Novartis | NVS - Ordinary Share Capital


Novartis reported $1.92B in Ordinary Share Capital for its fiscal quarter ending in September of 2025.





Ordinary Share Capital Change Date
AbbVie USD 1.77B 1.75B Jun/2025
Amgen USD 539M 1000K Dec/2025
AstraZeneca USD 1.55B 206K Dec/2025
Bausch Health Companies USD 370.53M 59K Dec/2025
Biogen USD 146.7M 200K Sep/2025
Bristol-Myers Squibb USD 2.04B 1.74B Sep/2025
Canopy Growth CAD 332.38M 127.23M Sep/2025
Corcept Therapeutics USD 105.12M 164K Sep/2025
Drreddys Laboratories INR 832.57M 53K Dec/2025
Eli Lilly USD 946.83M 354.23M Jun/2025
Gilead Sciences USD 1.24B 1000K Dec/2025
GlaxoSmithKline GBP 4.08B 49.43M Dec/2025
Glaxosmithkline GBP 4.03B 2.68B Sep/2025
J&J USD 2.41B 584K Sep/2025
Merck USD 2.49B 15.79M Sep/2025
Novartis USD 1.94B 23.4M Jun/2025
Novartis USD 1.92B 17.06M Sep/2025
Pacira USD 44.9M 44.85M Jun/2025
Perrigo USD 137.6M 0 Sep/2025
Pfizer USD 5.69B 1000K Sep/2025
Phibro Animal Health USD 4K 0 Sep/2024
Prestige Brands USD 48.08M 47.52M Sep/2025
Roche Holding CHF 795.62M 699.54K Dec/2025
Supernus Pharmaceuticals USD 57.12M 1000K Sep/2025
Zoetis USD 424.93M 16.54M Dec/2025